We have provided evidences that RIP3 depletion can reduce LPS-induced inflammation response (reduced pro-inflammatory cytokines release, decreased tissue MPO activity, decreased neutrophil influx and total protein concentration in BALF), attenuate LPS-induced lung injury, and alleviate hypothermia symptoms, which eventually improve survival rate in high dose LPS-induced severe ARDS in RIP3-KO mice. This evidence concerns the gene MPO and acute respiratory distress syndrome.